Clinical outcome of patients with acute myeloid leukemia (AML) is associated with
demographic and genetic features. Although the associations of acquired genetic alterations …

Myeloid leukemia associated with Down syndrome (ML-DS) has a unique molecular
landscape that differs from other subtypes of acute myeloid leukemia. ML-DS is often …

Acute myeloid leukemia (AML) has a poor prognosis and a heterogeneous mutation
landscape. Although common mutations are well-studied, little research has characterized …

NPM1 mutated acute myeloid leukemia (AML) comprises roughly 30% of all AML cases and
is mainly classified as favorable or intermediate-risk according to the European Leukemia …

Objectives The cryptic fusion oncogene NUP98:: NSD1 is known to be associated with FLT3‐
ITD mutation in acute myeloid leukemia (AML), and an independent poor prognostic factor in …

ABSTRACT Wilms' tumor gene 1 (WT1) is a transcription and post-translational factor that
has a crucial role in the biological and pathological processes of several human …

The Wilms tumor 1 (WT1) gene, located at locus 11p13, is a tumor suppressor gene that
encodes a zinc-finger transcription factor. 1, 2 The presence of WT1 gene mutation (mWT1) …

Abstract Introduction NPM1‐mutated (NPM1mut) myeloid neoplasms (MNs) with< 20% bone
marrow (BM) blasts (NPM1mut MNs< 20) are uncommon, and their classification remains …

Objective. To investigate the efficacy and safety of azacytidine and B‐cell
lymphoma/leukemia‐2 inhibitors in the treatment of patients with acute myeloid leukemia …

Breast cancer accounts for around 25% of all newly-diagnosed cancers, and is one of the
leading causes of cancer-related death in women due to a high rate of relapse and …